Altimmune Q4 2022 net loss $21.7M; cash $184.9M; pemvidutide obesity interim readout expected March 2023

Altimmune, Inc.

2022-FY EPS reported -$1.81 revenue$-68,000

Net loss for Q4 2022 was $21.7M ($0.43 per share) vs $23.9M ($0.57) in Q4 2021; revenue negligible.
Cash, cash equivalents and short-term investments totaled $184.9M at December 31, 2022.
R&D expenses $19.2M in Q4 2022, including $13.4M for pemvidutide and $1.9M for HepTcell.
MOMENTUM Phase 2 obesity trial 24-week interim readout expected in March 2023; Phase 2b NASH trial initiation expected mid-2023.
HepTcell Phase 2 enrollment >90% complete; data readout expected first half 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Altimmune, Inc. reported the three months ended December 31, 2022 results: net income $21.7 million, EPS $0.43 net loss per share.

Period: the three months ended December 31, 2022
Net income: $21.7 million
EPS: $0.43 net loss per share
Result: reported results

Exact text from the filing

Net loss for the three months ended December 31, 2022 was $21.7 million, or $0.43 net loss per share, compared to a net loss of $23.9 million, or $0.57 net loss per share, in the same period in 2021.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Altimmune, Inc. filing history →

Source: SEC EDGAR

accession 0001326190-23-000003

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.